Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 2,300 shares at $7.02 ($16K) on 2014-09-30, disclosed to the SEC on 2014-10-02.
Scheduled sale ($16k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |